RT Journal Article
SR Electronic
T1 Modafinil for Wakefulness in the Critical Care Units: A Literature Review and Case Series including COVID-19 Patients at a Tertiary Care Saudi Hospital
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.11.21250832
DO 10.1101/2021.02.11.21250832
A1 Amer, Marwa
A1 Bawazeer, Mohammed
A1 Butt, Abid Shahzad
A1 Dahhan, Talal I.
A1 Kseibi, Eiad
A1 Jamil, Mouhamad Ghyath
YR 2021
UL http://medrxiv.org/content/early/2021/02/19/2021.02.11.21250832.abstract
AB Cognitive improvement after critical illness is complex. Neuro-stimulants are used to speed up physical and mental processes through the increase in arousal, and wakefulness. In this case series, we reviewed the literature and described the effect of modafinil for wakefulness in a cohort of adult patients admitted to our COVID and non-COVID intensive care unit (ICU) between January 2017 and June 2020. A total of 8 patients included; 3 admitted to COVID-19, 4 surgical, and 1 transplant ICU. Obstructive sleep apnea was noted in 2 (25%), 2 patients (25 %) had an initial neuroimaging that showed hemorrhagic stroke, and 1 (12.5%) showed ischemic stroke with hemorrhagic transformation. Modafinil 100-200 mg daily was started for a median duration of 4 days and the median initiation time in relation to ICU admission was 11 (IQR 9-17) days. Glasgow coma Scale improvement was noted on 5 patients (62.5%). The median duration of mechanical ventilation was 17.5 (IQR 15-31.75) days, and the median ICU stay was 28.5 (IQR 20.25-48) days. All-cause mortality rate was 25 % at 28 days and 62.5 % at 90 days. Modafinil prevented tracheostomy in 1 COVID-19 patient. No significant adverse drug reactions were documented. In our case series, we described our experience for modafinil use for wakefulness in ICU ventilated patients including COVID-19 patients. Based on our observations, the known effects of modafinil, and its safety profile, it holds the potential to facilitate recovery from cognitive impairment. Larger studies are warranted to fully evaluate its role for this indication.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04751227Funding StatementNoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by King Faisal Specialist Hospital and Research Center (KFSHRC) Research Ethics Committee and Clinical Research Committee RAC # 2201230. The patient's written consent to publish was taken for each case included in the seriesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets used and analyzed during the current report are available from the corresponding author on reasonable request. (AKI)acute kidney injury(ARDS)acute respiratory distress syndrome(ADRs)adverse drug reactions(CSF)cerebrospinal fluid(CT)computed tomography(COVID-19)coronavirus disease 2019(CNS)central nervous system(CRRT)continuous renal replacement therapies(DVT)deep vein thrombosis(DM-2)diabetes type 2(DIC)disseminated intravascular coagulation(DNR)do-not-resuscitate(ESRD)end-stage renal disease(EVD)external ventricular drain(EEG)electroencephalogram(EMG and NCS)electromyogram and nerve conduction study(ED)emergency department(ESS)epworth sleepiness scale(EDS)excessive daytime sleepiness(FSS)fatigue severity scale(GCS)Glasgow Coma Scale(GBS)Guillian Barré syndrome(GABA)gamma-aminobutyric acid(GIB)gastrointestinal bleeding(HIT)heparin-induced thrombocytopenia(HCV)hepatitis C virus(HFpEF)heart failure with preserved ejection fraction(HD)hemodialysis(ICU)intensive care unit(IVIG)intravenous immunoglobulin(ICH)intracranial bleeding(IVH)intraventricular hemorrhage(KFSH&RC)King Faisal Specialist Hospital and Research Centre(LOC)level of consciousness(LP)lumbar puncture(MERS)Middle East respiratory syndrome(MI)myocardial infarction(MCS)minimally conscious state(MCA)middle cerebral artery(MRI)magnetic resonance imaging(NMB)neuromuscular blocking agents(OR)operating room(PADIS)Pain, Agitation/ Sedation, Delirium, Immobility, and Sleep Disruption(RRT)renal replacement therapy(SARS-CoV-2)severe acute respiratory syndrome coronavirus 2(SAH)subarachnoid hemorrhage(TBI)traumatic brain injury(VS)vegetative state